The conversation discusses the differences in inactive ingredients between Sandoz 5mg Finasteride and Proscar/Propecia, questioning the purpose of certain additives like Docusate sodium. It seeks to determine if these differences affect the effectiveness of the treatment for hair loss.
A user taking dutasteride and minoxidil for hair loss is considering adding RU58841 to their regimen due to unsatisfactory results. Other users suggest alternatives and discuss the potential temporary benefits and limitations of RU58841.
A user is considering dutasteride mesotherapy versus oral finasteride for hair loss, with concerns about side effects. Other users share experiences with both treatments, suggesting oral finasteride as more effective and cost-efficient, while also discussing the use of minoxidil, alfatradiol, and potential side effects like gynecomastia.
Morr F Aqua, an alcohol-free Minoxidil, is discussed for its absorption effectiveness. Users also mention using finasteride and RU58841 for hair loss treatment.
The conversation discusses using RU58841, a research chemical, for hair loss treatment. The user plans to use it due to side effects from finasteride and minoxidil, despite skepticism about its effectiveness and lack of FDA approval.
Alfatradiol is considered safe but less effective than finasteride for hair loss. One user reported subtle regrowth using alfatradiol with finasteride and minoxidil, while another found alfatradiol ineffective.
The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.
Pyrilutamide from Ligand Chem was used by several individuals to address hair loss, with mixed results and no significant side effects reported. Some users switched to Minoxidil Max for better value, while others noted no hair growth or only a reduction in shedding.
RU58841 caused severe side effects like heart palpitations and shortness of breath, leading the user to stop using it. Minoxidil and finasteride were effective without side effects, while RU58841's safety and effectiveness remain uncertain.
The user shared their 6-month progress using 0.25 mg finasteride, topical minoxidil, and dermastamping, noting good results but experiencing increased sleepiness. Another user suggested minoxidil might be causing the sleepiness, and the original poster considered adjusting their treatment.
Using PRP or Exosome treatments alongside Finasteride/Dutasteride and Minoxidil may not significantly enhance results. Dutasteride and oral Minoxidil are considered more effective options.
Dutasteride mesotherapy, combined with peptides and exosomes, is being considered for hair loss treatment. One user suggests that oral finasteride or dutasteride mesotherapy may not be necessary if already taking oral dutasteride.
The user is considering switching to topical finasteride or pyrilutamide to stabilize hair loss before a hair transplant, currently using oral minoxidil and finasteride. Suggestions include sticking to the current regimen as it is already potent, and caution against using pyrilutamide from unreliable sources.
Reducing the dose of RU58841 from 25mg to 7.5mg topically helped minimize heart palpitations. Users discussed the cardiac effects of RU58841 and minoxidil, noting that no treatment is completely free of side effects.
The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.
Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.
The user is considering starting Minoxidil and is looking for a topical solution to combine with it. They are confused about which product to prioritize among options like RU58841, Pyrilutamide, FinaTopic, and DutaTopic.
The user experiences severe side effects from finasteride and dutasteride, including low libido and anxiety, and is currently using oral minoxidil despite shortness of breath. They are seeking alternative treatments for hair loss, having tried pyrilutamide, fluridil, and RU58841 with no success, and are considering future treatments or a hair transplant.
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
The user cannot handle Minoxidil and is looking for an alternative to dilute topical finasteride. They are considering using Alpecin liquid as a solution.
RU58841 was used by some for hair loss, but concerns about side effects like gynecomastia and safety were raised. Alternatives like finasteride, minoxidil, pyrilutamide, and alfatradiol were discussed, with some users reporting better experiences with these treatments.
RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.
Finasteride and dutasteride may increase estrogen levels, leading to water retention and a fuller face. Users discuss managing these effects with lifestyle changes and supplements like zinc and DIM.
A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.
The user is using 5% Minoxidil and 0.1% topical Finasteride and is considering adding 0.5mg Dutasteride every 5 days to stabilize hair regrowth. Consistency with treatment is advised, and there is no strong evidence linking Finasteride or Dutasteride to fertility issues.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.